JP2020531423A5 - - Google Patents

Download PDF

Info

Publication number
JP2020531423A5
JP2020531423A5 JP2020508394A JP2020508394A JP2020531423A5 JP 2020531423 A5 JP2020531423 A5 JP 2020531423A5 JP 2020508394 A JP2020508394 A JP 2020508394A JP 2020508394 A JP2020508394 A JP 2020508394A JP 2020531423 A5 JP2020531423 A5 JP 2020531423A5
Authority
JP
Japan
Prior art keywords
cancer
substituted
pharmaceutical composition
alkyl
hydroxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020508394A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020531423A (ja
JP7267993B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/046541 external-priority patent/WO2019036377A1/en
Publication of JP2020531423A publication Critical patent/JP2020531423A/ja
Publication of JP2020531423A5 publication Critical patent/JP2020531423A5/ja
Application granted granted Critical
Publication of JP7267993B2 publication Critical patent/JP7267993B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020508394A 2017-08-15 2018-08-13 ヒストンメチルトランスフェラーゼ阻害剤としての三環式化合物 Active JP7267993B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762545936P 2017-08-15 2017-08-15
US62/545,936 2017-08-15
US201862712864P 2018-07-31 2018-07-31
US62/712,864 2018-07-31
PCT/US2018/046541 WO2019036377A1 (en) 2017-08-15 2018-08-13 TRICYCLIC COMPOUNDS AS HISTONE INHIBITORS METHYLTRANSFERASES

Publications (3)

Publication Number Publication Date
JP2020531423A JP2020531423A (ja) 2020-11-05
JP2020531423A5 true JP2020531423A5 (enExample) 2021-09-30
JP7267993B2 JP7267993B2 (ja) 2023-05-02

Family

ID=63452724

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020508394A Active JP7267993B2 (ja) 2017-08-15 2018-08-13 ヒストンメチルトランスフェラーゼ阻害剤としての三環式化合物

Country Status (13)

Country Link
US (1) US11661410B2 (enExample)
EP (1) EP3668863B1 (enExample)
JP (1) JP7267993B2 (enExample)
CN (1) CN111372927A (enExample)
BR (1) BR112020003073A2 (enExample)
ES (1) ES3016407T3 (enExample)
IL (1) IL272507A (enExample)
MX (1) MX2020001825A (enExample)
SA (1) SA520411303B1 (enExample)
SG (1) SG11202001090WA (enExample)
TW (1) TW201920136A (enExample)
WO (1) WO2019036377A1 (enExample)
ZA (1) ZA202001503B (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3612181A4 (en) 2017-04-21 2021-01-06 Epizyme, Inc. Combination therapies with ehmt2 inhibitors
WO2019036384A1 (en) 2017-08-15 2019-02-21 Global Blood Therapeutics, Inc. TRICYCLIC COMPOUNDS AS HISTONE INHIBITORS METHYLTRANSFERASES
CA3239101A1 (en) * 2021-11-25 2023-06-01 Gang Deng Tricyclic derivative and preparation method therefor and application thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4107288A (en) 1974-09-18 1978-08-15 Pharmaceutical Society Of Victoria Injectable compositions, nanoparticles useful therein, and process of manufacturing same
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US20170000784A1 (en) 2013-12-08 2017-01-05 Van Andel Research Institute Autophagy Inhibitors
US9284272B2 (en) * 2014-03-28 2016-03-15 Abbvie Inc. Inhibitors of histone methyltransferase G9a
US9840500B2 (en) 2014-06-16 2017-12-12 Fundación Para La Investigación Médica Aplicada Compounds as dual inhibitors of histone methyltransferases and DNA methyltransferases
WO2017102677A1 (en) 2015-12-14 2017-06-22 Fundación Para La Investigación Médica Aplicada 2,4,6,7-tetrasubstituted quinoline compounds as inhibitors of dna methyltransferases
US11254651B2 (en) 2016-02-17 2022-02-22 Global Blood Therapeutics, Inc. Histone methyltransferase inhibitors
WO2019036384A1 (en) 2017-08-15 2019-02-21 Global Blood Therapeutics, Inc. TRICYCLIC COMPOUNDS AS HISTONE INHIBITORS METHYLTRANSFERASES

Similar Documents

Publication Publication Date Title
RU2015143717A (ru) 2-Аминопиримидин-6-оны и аналоги, проявляющие противораковые и антипролиферативные действия
IL277783B1 (en) SHP2 inhibitory compositions, methods for treating cancer and methods for identifying a subject with SHP2 mutations
JP2020531423A5 (enExample)
JP2020504716A5 (enExample)
JP2016516702A5 (enExample)
JP2015502979A5 (enExample)
JP2024113019A5 (enExample)
JP2016519147A5 (enExample)
JP2020172535A5 (enExample)
JP2019535720A5 (enExample)
JP2020515571A5 (enExample)
JP2020508302A5 (enExample)
JP2017537114A5 (enExample)
US12358906B2 (en) Urea compounds and compositions as SMARCA2/BRM ATPase inhibitors
JP2022137047A5 (enExample)
RU2012151012A (ru) Циклопропиловые дикарбоксамиды и аналоги, обладающие противораковым и антипролиферативным действием
KR20220024191A (ko) 항암제 조합 요법
US20240246915A1 (en) Aminonaphthoquinone compounds and pharmaceutical composition for blocking ubiquitination-proteasome system in diseases
RU2010128107A (ru) Лечение рака ингибиторами топоизомеразы в комбинации с ингибиторами parp
JP2017509682A5 (enExample)
JP2008528467A5 (enExample)
JP2020510032A5 (enExample)
RU2014121073A (ru) Бициклические соединения пиперазина
JP2016513661A5 (enExample)
RU2015148359A (ru) Хиназолины и азахиназолины - двойные ингибиторы путей ras/raf/mek/erk и pi3k/akt/pten/mtor